Click any corner to turn the page.

March 24-25, 2015 Tokyo, Japan

Learn more about Biotechnology at bio.org-3-

Who should attend?Drug development and discovery companies

Medical technology companies

Universities and institutes

Intellectual property and legal organizations

Investors and financial services providers

Bio-clusters and incubators

Government and public support agencies

✓

✓

✓

✓

✓

✓

✓

The BIO Asia International Conference, co-hosted by the Biotechnology Industry Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market.

Mr. Osamu NagayamaPresident, JBA and Chairman & CEO, Chugai Pharmaceutical Co., Ltd.

Dr. Tatsuya KondoChief Executive, Pharmaceuticals and Medical Devices Agency (PMDA) Japan

Dr. Flemming Ornskov, MDCEO, Shire

Keynote Speakers

-4-

To support the market growth goals of our attendees, and in response to significant shifts in the regulatory landscape, this year’s event will feature expanded programming.

Japan's Journey in Creating an Attractive & Competitive Pharmaceutical MarketAdjustments to development policy and market infrastructures have contributed to notable growth in Japan and other countries in the Asia Pacific region recently. This panel will look at those and other factors to identify segments of the industry encountering the greatest changes and most significant opportunities in the region.

Moderator• Harrison Cook, Vice President, International Affairs, Eli Lilly

Panelist:• Stephen Anderson PhD., Commercial Attaché, United States Embassy, Tokyo, Japan• Simon Collier, Head of Governmental Affairs, Bayer Yakuhin, Ltd.

Accelerating Innovation: Lessons from Recent Policy Reforms and Successful Funding ModelsRegulatory changes within the past two years have attempted to motivate and accelerate innovation specifically as a result of Japan’s Act on Promotion of Healthcare Policy and the Plan for Promotion of Medical Research and Development. The panel will look at examples such as key shifts to accelerate regenerative medicine and new investments in novel business models, such as the GHIT Fund, that facilitate public-private collaboration in translation research and product development in infectious disease. Discussion will focus on the progress achieved, lessons learned, and implications for future policy adjustments that steer support to particular research areas.

Moderator• Jay P. Siegel, MD, Chief Biotechnology Officer and Head, Scientific Strategy & Policy, Johnson & Johnson

Panelist:• Gil Van Bokkelen, PhD, Chairman and CEO, Athersys • BT Slingsby, MD, PhD, MPH, CEO & Executive Director, Global Health Innovative Technology Fund

Panel Discussions

Speakers added daily.

Keynote Speakers

-5-

Emerging Deal-Making Trends in JapanThe thought leaders on this panel will discuss successes and challenges of their most recent Japan deals. The panelists will examine the advantages of western biotech companies doing Japan and/or Asia regional deals as part of an overall financing strategy, and how “traditional” western venture capital and equity funding comes into play.  The panel will also discuss key success factors that improve the probability of successfully consummating a deal in Japan, as well as ideas on how to expedite the entire due diligence and deal process with companies in Japan.   

Moderator• Steven Engen, Senior Vice President, Locust Walk Partners

Panelists• Neil Abdollahian, Managing Director, Clarity Point Partners • Arlene M. Morris, President & CEO, Syndax Pharmaceuticals • Goro Takeda, Venture Partner, Soffinova Ventures

A New Frontier in Industry-Academic Collaborations: Lessons Learned across a Portfolio of Partnership TypesAstraZeneca has forged a variety of long-term research collaboration and business development relationships with academic institutions across Asia.  The panelists will discuss the variety of partner identification processes that started their industry/academic relationships and what characteristics make one large pharma want to learn more about a potential partner.  Panelists will also evaluate the progress of these mature partnerships, describing lessons learned about which management habits should be repeated and which avoided for successful projects.  Senior designers of these partnerships will then share their vision for the future of academic/industry collaborations in Asia.

Moderator• Craig D. Wegner, PhD, Exec. Director & Head, Emerging Innovations Unit, Scientific Partnering & Alliances,

AstraZeneca Innovative Medicines and Early DevelopmentPanelists

• Keunchil Park, MD, PhD, Professor/Director, Division of Hematology/Oncology, Innovative Cancer Medicine Institute, Samsung Medical Center (SMC) / AstraZeneca Partnership on Gastric Cancer

• May Wang, PhD, Senior VP, Head of BD & Strategic Alliances, Hutchinson MediPharma Limited (HMP) / AstraZeneca Co-development Partnership for Volitinib

• Andrew H.-J. Wang, PhD, Co-director, National Research Program for Biopharmaceuticals (NRPB) / AstraZeneca Open Innovation Program for Advancement of Translational Medical Research and Drug Repositioning

• Xiang Jing Yao, MD, Professor, Graduate School of Medicine, Osaka University Hospital, AstraZeneca Open Innovation Collaboration in Cardiovascular Diseases

Panel Discussions

-6-

Building the Future: Characteristics of Successful Translational Research & Biotech IncubatorsThis panel will examine how university incubators and biocluster efforts in Japan are finding new and better approaches to helping people transfer IP into sustainable new businesses that grow the biotechnology industry.

Moderator • Masuhiro Kato, PhD, Project Professor, Translational Research Initiative (TRI), The University of Tokyo

Panelists• Hiromichi Kimura, PhD, Chairman, Medical Industry Innovation Institute; Professor, Graduate School of

Pharmaceutical Science, The University of Tokyo; Founder and Partner, Life Science Management, Inc.; Founder and CEO, Fast Track Initiative, Inc.

• Marc Sedam, Associate Vice Provost for Innovation and New Ventures, University of New Hampshire and Vice President for Professional Development and Board Member, Association of University Technology Managers (AUTM)

• Toru Seo, PhD, Head of External R&D Innovation (ERDI) Japan, Pfizer Inc.

Building a Strategy for Japan, and BeyondThe changing landscape for innovation and product development in Japan means new opportunities for corporate and business development. The question is how to pursue them. Our experts will layout the components for building a Japan strategy and how it is relevant to thinking about Asia.

Moderator• David Flores, President and CEO, BioCentury

Panelists• John Glasspool, Global Head-Emerging Therapies and Market Development, Baxter BioScience • Dan Paterson, Chief Operating Officer, Verastem • Rami Suzuki, PhD, President, Senior Group Officer, Global Business Development Unit, Eisai Co., Ltd.• Hidetoshi Torami, Executive Vice President and CFO, Sosei Group Corporation

Panel Discussions

Speakers added daily.

-7-

TuesdayMarch 24, 2015

Programming and Education

(Coriander)

Company Presentations (13 minutes)

(Drawing Room)

Partnering Timeslots (25 minutes)

(Tarragon/GBR East)

8:00 – 8:55am Networking Breakfast (Grand Ballroom West)

9:00 – 9:20amWelcome Remarks from James C. Greenwood, President & CEO, Biotechnology Industry Organization

(Grand Ballroom West)

9:20 – 9:55amOpening Plenary: Keynote Speech by Dr. Tatsuya Kondo,

Chief Executive, Pharmaceutical and Medical Devices Agency, Japan (Grand Ballroom West)

10:00 –10:25amTesoRx

Partnering meeting #1DS Pharma Animal Health

10:30 – 10:55am Japan’s Journey in Creating an Attrac-tive & Competitive Pharmaceutical

Market

Partnering meeting #2

11:00 – 11:25am Partnering meeting #3

11:30 – 11:55am Cennerv Pharma Partnering meeting #4Tonix Pharmaceuticals

12:00 – 12:55pm

Luncheon Plenary: Keynote Speech with Mr. Osamu Nagayama,Chairman & CEO, Chugai Pharmaceutical Co., Ltd.;

President, Japan Bioindustry Association(Grand Ballroom West)

1:00 – 1:55pm

Spectrum PharmaceuticalsPartnering meeting #5Aptose Biosciences

Chugai PharmaceuticalsPartnering meeting #6Athersys

2:00 – 2:55pm

Asterias BiotherapeuticsPartnering meeting #7

Regience K.K.RepliCel Life Sciences

Partnering meeting #8Zafgen

3:00 – 3:55pm

Chiome Biosciences, Inc.Partnering meeting #9

GenSperaOP BIO FACTORY

Partnering meeting #10Skyepharma AG

4:00 – 4:55pmAccelerating Innovation: Lessons from Recent Policy Reforms and Successful

Funding Models

Experimental Therapeutics CentrePartnering meeting #11Sirona Biochem Corp.

DiaMedica Corporation Partnering meeting #12Enterome

5:00 – 5:55pmPartnering meeting #13

Partnering meeting #14

6:00 – 7:30pm Opening Reception(Roppongi Hills Club)

Agenda*

-8-

WednesdayMarch 25, 2015

Programming and Education

(Coriander)

Company Presentations (13 minutes)

(Drawing Room)

Partnering Timeslots (25 minutes)

(Tarragon/GBR East)

8:00 – 8:55amNetworking Breakfast(Grand Ballroom West)

Partnering meeting #16

Partnering meeting #15

9:00 – 9:55am Emerging Deal-Making Trends in Japan

Partnering meeting #17

Partnering meeting #18

10:00 –10:25amGalena Biopharma

Partnering meeting #19Verastem

10:30 –10:55am A New Frontier in Industry-Academic Collaborations: Lessons Learned Across a Portfolio of Partnership

Types (AstraZeneca)

Synta PharmaPartnering meeting #20

Molcure

11:00 – 11:25am Frost Biologic Partnering meeting #21Rexahn Pharmaceuticals

11:30 – 11:55am The Wellcome Trust Partnering meeting #22Pfizer Inc.

12:00 – 12:55pm

Luncheon Plenary: Keynote with Dr. Flemming Ornskov, CEO, Shire

(Grand Ballroom West)

1:00 – 1:25pmBaxter

Partnering meeting #23Protein Sciences

1:30 – 1:55pmOpsona Therapeutics

Partnering meeting #24Sunesis Pharmaceuticals

2:00 – 2:25pmTetraphase Pharmaceuticals

Partnering meeting #25M Bio Technology

2:30 – 2:55pm Building the Future: Characteristics of Successful Translational Research

& Biotech Incubators

Materia Medica HoldingPartnering meeting #26

Nomadic Bioscience

3:00 – 3:25pmPrevenTec

Partnering meeting #27ReqMed Company

3:30 – 3:55pmMakindus

Partnering meeting #28Richcore Life Sciences

4:00 – 4:55pm Building a Strategy for Japan, and Beyond

Partnering meeting #29

Partnering meeting #30

5:00 – 5:55pm Closing Reception (Location TBD)Partnering meeting #31

Partnering meeting #32

* As of 3/4/2015

*Schedule subject to revision as speakers’ schedules and industry needs warrant.Program as of February 27, 2015

-9-

BIO’s One-on-One Partnering™ System is the interactive environment that allows you to increase your productivity, discover new investment and licensing opportunities, and expand your business potential worldwide. Using the system, companies are able to:

• Pre-schedule 25-minute private 1x1 meetings• Source potential collaborations and funding opportunities

with an international audience• Communicate directly with prospective investors and C-level

executives in biotech and pharma• Search company and investor profiles for potential business

partnerships

 2014 Statistics• Over 400 delegates attended from 24 countries • Over 830 One-on-One PartneringTM meetings • More than 130 companies represented

Attendee Breakdown• 76% of attendees are from biopharma companies

• 65% of attendees are at the director level or above

Partnering & Presenting Companies

Aptose Biosciences, Inc.Asterias BiotherapeuticsAthersys, Inc.BaxterCennerv Pharma Pte. Ltd.Chiome Biosciences, Inc.Chugai Pharmaceuticals Co., Ltd.DiaMedica CorporationDS Pharma Animal Health Co., Ltd.EnteromeExperimental Therapeutics CentreFrost BiologicGalena BiopharmaGenSpera, Inc.M Bio Technology, Inc.MakindusMateria Medica HoldingMolcureNomadic Bioscience Co., Ltd.OP BIO FACTORY Co., Ltd.Opsona TherapeuticsPfizer Inc.PrevenTec Inc.Protein SciencesRegience K.K.RepliCel Life Sciences Inc.ReqMed Company, Ltd.Rexahn PharmaceuticalsRichcore Lifesciences Pvt. Ltd.Sirona Biochem Corp.Skyepharma AGSpectrum PharmaceuticalsSunesis PharmaceuticalsSynta PharmaTesoRxTetraphase PharmaceuticalsThe Wellcome TrustTonix PharmaceuticalsVerastemZafgen

* As of 3/4/2015

Presenting Companies*

-10-

Sponsors

Sponsorship Opportunities Still Available BIO sponsors receive top-notch customer service, prime brand exposure and recognition from the most influential people in biotech. Let us build a sponsorship package that meets your needs. Contact Sara Morgenstern at 202-449-6381 or smorgenstern@bio.org to get started. For more information on BIO sponsorships, please visit www.bio.org/sponsor

BIO Helix Sponsors

Conference Sponsors

Media Partners

Co-Hosts

BIO Double Helix Sponsors

-11-

Andrew DickinsonManaging Director, Lazard

Reiri MiuraDeputy Director, Corporate Strategy, Taiho Pharmaceutical Co., Ltd.

Ted TanakaPartnering Consultant, Tanaka International LLC

Advisory Committee

Steve EngenJapan/Asia Advisor, Verastem

Marc SedamAssociate Vice Provost of Innovation and New Ventures, UNHInnovation And Vice President for Professional Development and Board Member, AUTM

Yoshiaki TsukamotoExecutive Director, Japan Bioindustry Association

John GlasspoolGlobal Head-Emerging Therapies and Market Development, Baxter BioScience

BT Slingsby, MD, PhD, MPH.CEO, Global Health Innovative Technology Fund

Alan VanderborghtCEO, Torreya Emerging Markets

Tetsuyuki Maruyama, PhDGeneral Manager, Pharmaceuticals Research Division, Takeda Pharmaceutical Co., Ltd.

Goro TakedaManaging Partner, FinTech Global Capital & Venture Partner, Sofinnova Ventures

Craig Wegner, PhDExecutive Director & Head, Boston Emerging Innovations Unit, Scientific Partnering & Alli-ances, AstraZeneca IMED R&D

Join the conversation:Learn more about Biotechnology at bio.orgEngage with the Biotech Community at BIOtech-NOW.orgFollow us on Twitter @bio1x1Tweet with the official conference hashtag #BIOASIA15Become a fan on Facebook (facebook.com/IAmBiotech)

-12-

Reserve your spot today!

Hotel VenueGrand Hyatt Tokyo 6-10-3 Roppongi, Minato-Ku Tokyo, Japan 106-0032 Phone: 81-3-4333-1234

Registration Packages

U.S./ ROW Attendee Fees - Registration Only (per person)

Member Non-MemberAttendee Fee Per Person $2,299 $2,899Investors $999

Asia-Pacific Attendee Fees - Registration Only

Attendee Rates per Person (in JPY)Regular Rate 120,000Additional Attendee Fee 75,000Discovery Attendee Fee 50,000Government/Academic Fee 50,000Translator 30,000